SCHEMBL21221261

SCHEMBL21221261

CCOC(=O)C(CC(C)C)NC(=O)CCC(=O)N[C@H](Cc1ccc(-c2ccccc2)cc1)C[C@@H](C)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 13/20 0.71
▸ ACE P12821 4/20 0.71
▸ MMEL1 Q495T6 8/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21221260 1.00 MME (0.71) MMEACEMMEL1
SCHEMBL21221259 1.00 MME (0.71) MMEACEMMEL1
SCHEMBL21241439 0.95 MME (0.63) MMEACEMMEL1
SCHEMBL28460902 0.95 MME (0.63) MMEACEMMEL1
SCHEMBL28460897 0.95 MME (0.63) MMEACEMMEL1
SCHEMBL21221283 0.92 MME (0.65) MMEACEMMEL1
SCHEMBL21221282 0.92 MME (0.65) MMEACEMMEL1
SCHEMBL7436015 0.89 MME (0.76) MMEACEMMEL1
SCHEMBL28456484 0.89 MME (0.76) MMEACEMMEL1
SCHEMBL21221276 0.87 MME (0.66) MMEACEMMEL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3778557-A1 COMBINATIONS COMPRISING A SUBSTITUTED BIPHENYLBUTANOIC ESTER DERIVATIVE AS NEP INHIBITOR AND VALSARTAN Novartis AG (CH) 2021-02-17 — — EP claimed
EP-3544966-B1 SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS NOVARTIS AG (CH) 2020-09-09 — — EP claimed
US-20200246295-A1 SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) 2020-08-06 — — US claimed
US-10668035-B2 Substituted bisphenyl butanoic ester derivatives as NEP inhibitors NOVARTIS AG (CH) 2020-06-02 — — US claimed
US-20190240177-A1 SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) 2019-08-08 — — US claimed
EP-3778557-A1 COMBINATIONS COMPRISING A SUBSTITUTED BIPHENYLBUTANOIC ESTER DERIVATIVE AS NEP INHIBITOR AND VALSARTAN Novartis AG (CH) 2021-02-17 — — EP disclosed
CN-111655671-A Substituted bisphenyl butyrate derivatives as NEP inhibitors 诺华股份有限公司 2020-09-11 — — CN disclosed
EP-3544966-B1 SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS NOVARTIS AG (CH) 2020-09-09 — — EP disclosed
US-20200246295-A1 SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) 2020-08-06 — — US disclosed
US-10668035-B2 Substituted bisphenyl butanoic ester derivatives as NEP inhibitors NOVARTIS AG (CH) 2020-06-02 — — US disclosed
US-20190240177-A1 SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) 2019-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10668035-B2 Substituted bisphenyl butanoic ester derivatives as NEP inhibitors MME, REN, ECE1 MME 1/4885ACE 4/4885MMEL1 606/4885
US-20200246295-A1 SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS MME, REN, ECE1 MME 1/4885ACE 4/4885MMEL1 606/4885
US-20190240177-A1 SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS MME, REN, ECE1 MME 1/4885ACE 4/4885MMEL1 606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback